Deutsche Bank Starts Legend Biotech Corp. (LEGN) at Buy

Deutsche Bank analyst James Shin initiates coverage on Legend Biotech Corp. (NASDAQ: LEGN) with a Buy rating and a price target of $60.00.

The analyst comments "Big picture – We are initiating coverage of LEGN with a Buy rating and $60 PT based on our view that Carvykti sales should benefit in 2H24 from expanded patient slot and manufacturing capacity. More near term for LEGN’s stock, we think Carvykti’s CARTITUDE-2 (Cohort D – Newly Diagnosed Myeloma with

For an analyst ratings summary and ratings history on Legend Biotech Corp. click here. For more ratings news on Legend Biotech Corp. click here.

Shares of Legend Biotech Corp. closed at $42.60 yesterday.

You May Also Be Interested In

• Oppenheimer Downgrades Legend Biotech Corp. (LEGN) to Perform, 'CEO/Partnership/Competition Overhangs to Cap Upside'
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)